AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23464951 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) and unsupervised at-home range of motion exercises
Number of subjects: 70
Study 23464951 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy with a licensed therapist
Number of subjects: 70
Study 21439528 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-dose heparin (2,000 IU)
Number of subjects: 465
Study 21439528 — intervention group
Group type: COMPARATOR
Intervention: Low-dose heparin (5,000 IU)
Number of subjects: 465
Study 18192671 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (0.1 mg triptorelin) administered 6 days after ICSI
Number of subjects: 570
Study 18192671 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 6 days after ICSI
Number of subjects: 570
Study 16611715 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipstick proteinuria 1+
Number of subjects: 12866
Study 16611715 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipstick proteinuria >=2+
Number of subjects: 12866
Study 16611715 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR <60 ml/min per 1.73 m²
Number of subjects: 12866
Study 16611715 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR <60 ml/min per 1.73 m² and >=2+ proteinuria
Number of subjects: 12866
Study 14606990 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 0
Study 10960754 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrostatic pressure of 15cm H(2)O
Number of subjects: 30
Study 10960754 — intervention group
Group type: COMPARATOR
Intervention: No hydrostatic pressure
Number of subjects: 30
Study 8780073 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl
Number of subjects: 24
Study 1740861 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational memorandum outlining vaccine indications
Number of subjects: 442
Study 1740861 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal letter mailed to a random sample of half of the remaining unimmunized persons
Number of subjects: 442
Study 1740861 — intervention group
Group type: COMPARATOR
Intervention: No-letter controls
Number of subjects: 442
Study 1740861 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call to half of the unimmunized letter recipients
Number of subjects: 442
Study 1740861 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine offered directly in clinics and conferences
Number of subjects: 442
Study 1740861 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall immunization rate at completion of the study
Number of subjects: 442
Study 6430053 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose NTG patches (n = 7)
Number of subjects: 14
Study 6430053 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximally tolerated NTG patches (first type, n = 8, mean NTG dose delivered 25 mg)
Number of subjects: 14
Study 6430053 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximally tolerated NTG patches (second type, n = 5, mean NTG dose delivered 22 mg)
Number of subjects: 14
Study 6430053 — intervention group
Group type: COMPARATOR
Intervention: Sublingual NTG (positive control)
Number of subjects: 14
Study 30371767 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate invasive strategy (STEMI-like)
Number of subjects: 142
Study 30371767 — intervention group
Group type: COMPARATOR
Intervention: Delayed invasive strategy (NSTEMI-like)
Number of subjects: 142
Study 29470561 — intervention group
Group type: EXPERIMENTAL
Intervention: ePTFE-only group
Number of subjects: 129
Study 29470561 — intervention group
Group type: COMPARATOR
Intervention: ePTFE with conchal cartilage group
Number of subjects: 129
Study 29470561 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 129
Study 27447428 — intervention group
Group type: EXPERIMENTAL
Intervention: VEL015 (sodium selenate) 10 mg tds (n=20)
Number of subjects: 40
Study 27447428 — intervention group
Group type: COMPARATOR
Intervention: Control (VEL015 320μg tds [n=10] or placebo [n=10])
Number of subjects: 40
Study 24517114 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide 4 mg once daily for 10 days
Number of subjects: 36
Study 24517114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 23088906 — intervention group
Group type: EXPERIMENTAL
Intervention: CCBD (Continuous Controllable Balloon Dilator)
Number of subjects: 120
Study 23088906 — intervention group
Group type: COMPARATOR
Intervention: Mechanical dilation (Hegar dilator)
Number of subjects: 120
Study 20561625 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 g whey protein isolate
Number of subjects: 20
Study 20561625 — intervention group
Group type: COMPARATOR
Intervention: 45 g sodium caseinate
Number of subjects: 20
Study 20561625 — intervention group
Group type: COMPARATOR
Intervention: 45 g glucose control
Number of subjects: 20
Study 17318839 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumanirole, 1 to 16 mg/day
Number of subjects: 614
Study 17318839 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole, 0.75 to 24 mg/day
Number of subjects: 614
Study 17318839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study 15680855 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch solution
Number of subjects: 30
Study 15680855 — intervention group
Group type: COMPARATOR
Intervention: Ringer lactate solution
Number of subjects: 30
Study 15680855 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 16428575 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Unique
Number of subjects: 80
Study 16428575 — intervention group
Group type: COMPARATOR
Intervention: Cobra PLA
Number of subjects: 80
Study 16428575 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 80
Study 10839469 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine 2-8 mg/day
Number of subjects: 12
Study 8851895 — intervention group
Group type: EXPERIMENTAL
Intervention: Skirt group (wearing knee-length skirts)
Number of subjects: 12
Study 8851895 — intervention group
Group type: COMPARATOR
Intervention: Trouser group (wearing full trousers)
Number of subjects: 12
Study 1617494 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium monofluorophosphate-calcium carbonate (MFP-Ca) 100 mg with breakfast
Number of subjects: 10
Study 1617494 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride (NaF) 25 mg fasting
Number of subjects: 10
Study 1617494 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium monofluorophosphate-calcium carbonate (MFP-Ca)
Number of subjects: 10
Study 6393670 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH biosynthetic human insulin
Number of subjects: 8
Study 6393670 — intervention group
Group type: COMPARATOR
Intervention: NPH pork insulin
Number of subjects: 8
Study 31834152 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based vergence/accommodative therapy for intermittent exotropia (60 minutes once per week for 12 weeks)
Number of subjects: 14
Study 31834152 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based vergence/accommodative therapy for intermittent exotropia
Number of subjects: 14
Study 30092952 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1869
Study 30092952 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 1869
Study 30092952 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute renal failure (ARF) after PCI
Number of subjects: 1869
Study 30092952 — intervention group
Group type: COMPARATOR
Intervention: Acute renal failure (ARF) after CABG
Number of subjects: 1869
Study 30092952 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary composite endpoint (death, stroke, or MI) in patients with CKD
Number of subjects: 1869
Study 30092952 — intervention group
Group type: COMPARATOR
Intervention: Primary composite endpoint (death, stroke, or MI) in patients without CKD
Number of subjects: 1869
Study 26896263 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with Drug-Eluting Stents (DES)
Number of subjects: 86
Study 26896263 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal left main lesion with LVEF ≤45%
Number of subjects: 86
Study 26896263 — intervention group
Group type: EXPERIMENTAL
Intervention: High SYNTAX score
Number of subjects: 86
Study 26896263 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 86
Study 26896263 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patients with Diabetes, LVEF ≤ 45%, and SYNTAX score >32
Number of subjects: 86
Study 26896263 — intervention group
Group type: EXPERIMENTAL
Intervention: IC Stent, IVUS, or procedural strategy in distal lesion
Number of subjects: 86
Study 24658221 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose ethanol (0.6 g/kg for females, 0.7 g/kg for males)
Number of subjects: 9
Study 24658221 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose ethanol (1.2 g/kg for females, 1.4 g/kg for males)
Number of subjects: 9
Study 24658221 — intervention group
Group type: COMPARATOR
Intervention: Control (alcohol-free drinks)
Number of subjects: 9
Study 20974079 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation by videotapes
Number of subjects: 249
Study 20974079 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 249
Study 20974079 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation plus telephone counseling
Number of subjects: 249
Study 20974079 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 249
Study 21442587 — intervention group
Group type: EXPERIMENTAL
Intervention: Eagle Tactical Athlete Program (ETAP)
Number of subjects: 0
Study 21442587 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory testing of musculoskeletal, biomechanical, physiological, and nutritional characteristics
Number of subjects: 0
Study 21442587 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury surveillance
Number of subjects: 0
Study 18618943 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (30% carbohydrate, 40% protein, 30% fat)
Number of subjects: 10
Study 18618943 — intervention group
Group type: COMPARATOR
Intervention: Control diet (55% carbohydrate, 15% protein, 30% fat)
Number of subjects: 10
Study 18618943 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 10
Study 15740541 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenatoprazole 40 mg
Number of subjects: 24
Study 15740541 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg
Number of subjects: 24
Study 11919405 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous sodium ferric gluconate (6.25-21.3 mg in every hemodialysis session)
Number of subjects: 26
Study 11919405 — intervention group
Group type: COMPARATOR
Intervention: Intermittent sodium ferric gluconate (62.5 mg every 1-4 weeks)
Number of subjects: 26
Study 10562740 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundholding practices
Number of subjects: 52
Study 10562740 — intervention group
Group type: COMPARATOR
Intervention: Non-fundholding practices
Number of subjects: 52
Study 7717630 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleus 22 cochlear implant
Number of subjects: 0
Study 7717630 — intervention group
Group type: EXPERIMENTAL
Intervention: Smith & Nephew Richards Ineraid cochlear implant
Number of subjects: 0
Study 7717630 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M/Vienna cochlear implant
Number of subjects: 0
Study 7717630 — intervention group
Group type: COMPARATOR
Intervention: Multichannel devices (Nucleus 22 and Ineraid)
Number of subjects: 0
Study 31817080 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with caloric restriction of approximately 1673.6 kJ/day (400 kcal/day)
Number of subjects: 67
Study 31817080 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital diet
Number of subjects: 67
Study 27530332 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months training in Internet connectivity and social networking
Number of subjects: 76
Study 27530332 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 76
Study 27448761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ficlatuzumab plus gefitinib
Number of subjects: 188
Study 27448761 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 188
Study 25372149 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional group-based HIV/STI prevention intervention (traditional WORTH)
Number of subjects: 306
Study 25372149 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia group-based HIV/STI prevention intervention (multimedia WORTH)
Number of subjects: 306
Study 25372149 — intervention group
Group type: COMPARATOR
Intervention: Wellness Promotion intervention (control condition)
Number of subjects: 306
Study 23043926 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention combined with Tagamet 800 mg per evening p.o.
Number of subjects: 96
Study 23043926 — intervention group
Group type: COMPARATOR
Intervention: Tagamet 800 mg per evening p.o.
Number of subjects: 96
Study 19938712 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyexyethyl starch (HES) 200/0.5 ‐ Hemohes
Number of subjects: 36
Study 19938712 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 ‐ Voluven
Number of subjects: 36
Study 19938712 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified gelatin solution ‐ Gelofusin
Number of subjects: 36
Study 17450977 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-week course on Adapted Physical Education (APE)
Number of subjects: 81
Study 17450977 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 81
Study 15204150 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 658
Study 15204150 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroids (TCS)
Number of subjects: 658
Study 11588740 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation (therapeutical and neuromuscular exercises with occupational therapy with professional supervision)
Number of subjects: 60
Study 11588740 — intervention group
Group type: COMPARATOR
Intervention: Home-based rehabilitation (conventional exercises with family caregiver and limited professional supervision)
Number of subjects: 60
Study 9848512 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy supplementation (60-g soy supplement containing 45 mg isoflavones) taken daily for 14 days
Number of subjects: 48
Study 9848512 — intervention group
Group type: COMPARATOR
Intervention: Normal diet alone (Control)
Number of subjects: 48
Study 8079970 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate magnesium concentration of 0 mg/dL
Number of subjects: 8
Study 8079970 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate magnesium concentration of 0.6 mg/dL
Number of subjects: 8
Study 8079970 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate magnesium concentration of 1.8 mg/dL
Number of subjects: 8
Study 2589846 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine syrup
Number of subjects: 12
Study 2589846 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine solution
Number of subjects: 12
Study 2589846 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine capsule
Number of subjects: 12
Study 1039629 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-minute class in acupuncture and Chinese medicine
Number of subjects: 80
Study 1039629 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and post-tests
Number of subjects: 80
Study 31746078 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg prevalence assessment
Number of subjects: 2715
Study 31746078 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV exposure assessment
Number of subjects: 2715
Study 31746078 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-HCV prevalence assessment
Number of subjects: 2715
Study 31056306 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH isoforms in women with PCOS
Number of subjects: 112
Study 31056306 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH isoforms in women with PCOS combined with androgens and BMI
Number of subjects: 112
Study 28692467 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus-plus-infusion group (tranexamic acid 1g infusion for 8 hours)
Number of subjects: 168
Study 28692467 — intervention group
Group type: COMPARATOR
Intervention: Bolus group (placebo infusion for 8 hours)
Number of subjects: 168
Study 25941995 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom foot orthoses (CFO)
Number of subjects: 77
Study 25941995 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated foot orthoses (PFO)
Number of subjects: 77
Study 25941995 — intervention group
Group type: COMPARATOR
Intervention: Sham insole treatment
Number of subjects: 77
Study 25941995 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 77
Study 23464600 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative program using concept mapping
Number of subjects: 150
Study 23464600 — intervention group
Group type: COMPARATOR
Intervention: Traditional program
Number of subjects: 150
Study 21316752 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (4 mg on day 1 to 16 mg on days 3 to 7)
Number of subjects: 2029
Study 21316752 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 2029
Study 21316752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2029
Study 18192330 — intervention group
Group type: EXPERIMENTAL
Intervention: LC Star jet nebuliser
Number of subjects: 17
Study 18192330 — intervention group
Group type: EXPERIMENTAL
Intervention: LS 290 ultrasonic nebuliser
Number of subjects: 17
Study 18192330 — intervention group
Group type: EXPERIMENTAL
Intervention: Projet ultrasonic nebuliser
Number of subjects: 17
Study 16445306 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 3-12 mg/day
Number of subjects: 541
Study 16445306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 541
Study 14610122 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate at low plasma level (6 micromol/L [2 mg/L])
Number of subjects: 65
Study 14610122 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate at medium plasma level (31 micromol/L [10.5 mg/L])
Number of subjects: 65
Study 14610122 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate at high plasma level (56 micromol/L [19 mg/L])
Number of subjects: 65
Study 14610122 — intervention group
Group type: COMPARATOR
Intervention: Comparison of low vs medium plasma levels
Number of subjects: 65
Study 14610122 — intervention group
Group type: COMPARATOR
Intervention: Comparison of medium vs high plasma levels
Number of subjects: 65
Study 14610122 — intervention group
Group type: COMPARATOR
Intervention: Comparison of low vs high plasma levels
Number of subjects: 65
Study 10696124 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy leading to complete necrosis (CNWT)
Number of subjects: 599
Study 10696124 — intervention group
Group type: EXPERIMENTAL
Intervention: Stages I-III patients with CNWT
Number of subjects: 599
Study 10696124 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IV patients with CNWT
Number of subjects: 599
Study 10696124 — intervention group
Group type: EXPERIMENTAL
Intervention: Wilms tumors of blastemic pattern
Number of subjects: 599
Study 10696124 — intervention group
Group type: EXPERIMENTAL
Intervention: Wilms tumors with <10% viable tumor
Number of subjects: 599
Study 8730245 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d. plus amoxycillin 750 mg t.d.s. for 2 weeks
Number of subjects: 168
Study 8730245 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg t.d.s. plus amoxycillin 750 mg t.d.s. for 2 weeks
Number of subjects: 168
Study 8730245 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment in group I
Number of subjects: 168
Study 8730245 — intervention group
Group type: COMPARATOR
Intervention: Retreatment in group II
Number of subjects: 168
Study 1420747 — intervention group
Group type: EXPERIMENTAL
Intervention: High enzyme preparation ('Pancrease HL', Cilag)
Number of subjects: 0
Study 1420747 — intervention group
Group type: COMPARATOR
Intervention: Standard pancreatic enzyme supplement ('Creon', Duphar)
Number of subjects: 0
Study 3838343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX)
Number of subjects: 31
Study 3838343 — intervention group
Group type: COMPARATOR
Intervention: FAM' (5-fluorouracil, doxorubicin, mitomycin C)
Number of subjects: 31
Study 28579349 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic-guided placement (EMP)
Number of subjects: 155
Study 28579349 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic-guided placement (EGDP)
Number of subjects: 155
Study 26731179 — intervention group
Group type: EXPERIMENTAL
Intervention: UVCs
Number of subjects: 104
Study 26731179 — intervention group
Group type: EXPERIMENTAL
Intervention: PICCs
Number of subjects: 104
Study 25524399 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐determination Theory‐based intervention
Number of subjects: 0
Study 23342791 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixation
Number of subjects: 32
Study 23342791 — intervention group
Group type: COMPARATOR
Intervention: Traction
Number of subjects: 32
Study 19251828 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg
Number of subjects: 43
Study 19251828 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg
Number of subjects: 43
Study 19251828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 18363420 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 70
Study 18363420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 16078667 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral kidney transplantation with bilateral external iliac arteries anastomosed to the donors' renal arteries (Group A)
Number of subjects: 30
Study 16078667 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral external iliac arteries and the other internal iliac arteries anastomosed to the donors' renal arteries (Group B)
Number of subjects: 30
Study 16078667 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal iliac arteries anastomosed to the donors' renal arteries (Group C)
Number of subjects: 30
Study 12355035 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy
Number of subjects: 0